We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Thrombotargets and Specs Achieve Milestone in Drug Discovery Collaboration and Begin a new Anticoagulant Program
News

Thrombotargets and Specs Achieve Milestone in Drug Discovery Collaboration and Begin a new Anticoagulant Program

Thrombotargets and Specs Achieve Milestone in Drug Discovery Collaboration and Begin a new Anticoagulant Program
News

Thrombotargets and Specs Achieve Milestone in Drug Discovery Collaboration and Begin a new Anticoagulant Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Thrombotargets and Specs Achieve Milestone in Drug Discovery Collaboration and Begin a new Anticoagulant Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Since Specs and Thrombotargets Corp announced their drug discovery collaboration agreement, in 2006, Thrombotargets has carried out the HTS of specific library provided by Specs with its BioPlatformScreen ™ technology.

Thrombotargets has been able to identify some new anticoagulant small molecules.

The discovered hits exert an important potency and its therapeutical window is much wider than those of Heparins, Low Molecular Weight Heparins (LMWH) and other standard treatments.

“We are very excited and feel very optimistic regarding this success in our collaboration with Specs. In addition, these new hits will balance our present peptide-based and antibody-based anticoagulant programs” said Dr. Javier Pedreño, President and CEO of Thrombotargets Corp.

“We are confident that the combined power of our high quality screening compounds library and Thrombotargets’  BioPlatformScreen™ Technology will generate even more new projects“ said Johan Tijhuis, Specs’ CEO.

Thrombotargets and Specs have decided to continue Drug Discovery collaboration to take advantage of their respective technologies and know-how, in the Hit to Lead and Lead Optimization process.

Advertisement